Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.
American journal of clinical dermatology
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with =25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
European journal of cancer (Oxford, England : 1990)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-? and IL-12.
Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated ...
To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgi...
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head...
The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free foll...